STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
This is the online version of The Readout, STAT\u2019s flagship biotech newsletter<\/em>.\u00a0Sign up<\/a>\u00a0to get it in your inbox.<\/em><\/p>\n You\u2019re back. We\u2019re sort of back. It\u2019s Day 2 of JPM and we\u2019re definitely not exhausted or delirious yet.<\/p>\n This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We\u2019ve got a lot more news today, so let\u2019s get to it.<\/p>\n It\u2019s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\nThe next test for Kite Pharma \u2014 and Gilead<\/h2>\n